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Abstract
Background: In previous studies it has been found that in cell cultures of human adult ovaries there is a population of
small stem cells with diameters of 2–4 μm, which are present mainly in the ovarian surface epithelium and are
comparable to very small embryonic-like stem cells (VSELs) from bone marrow. These cells are not observed by
histopathologists in the ovarian tissue due to their small size and unknown clinical significance. Because these cells
express a degree of pluripotency, they might be involved in the manifestation of ovarian cancer. Therefore we studied
the ovarian tissue sections in women with borderline ovarian cancer and serous ovarian carcinoma to perhaps identify
the small putative stem cells in situ.
Methods: In 27 women with borderline ovarian cancer and 20 women with high-grade serous ovarian carcinoma the
ovarian tissue sections were stained, per standard practice, with eosin and hematoxylin staining and on NANOG, SSEA-4
and SOX2 markers, related to pluripotency, using immunohistochemistry. We focused on the presence and localization
of small putative stem cells with diameters of up to 5 μm and with the nuclei spread over nearly the full cell volume.
Results: In ovarian sections of both borderline ovarian cancer and serous ovarian carcinoma patients we were
able to identify the presence of small round cells complying with the above criteria. Some of these small cells
were NANOG-positive, were located among epithelial cells in the ovarian surface epithelium and as a single cell
or groups of cells/clusters in typical “chambers”, were found only in the presence of ovarian cancer and not in
healthy ovaries and are comparable to those in fetal ovaries. We envision that these small cells could be related
to NANOG-positive tumor-like structures and oocyte-like cells in similar “chambers” found in sections of cancerous ovaries,
which could support their stemness and pluripotency. Further immunohistochemistry revealed a similar population of
SSEA-4 and SOX2-positive cells.
Conclusions: We may conclude that putative small stem cells expressing markers, related to pluripotency, are present in
the ovarian tissue sections of women with borderline ovarian cancer and high-grade serous ovarian carcinoma
thus indicating their potential involvement in ovarian cancer.
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Background
Ovarian cancer is an aggressive disease affecting a large
population of women worldwide. It is difficult to diag-
nose early because of a lack of symptoms, and it can be
quite resistant to treatment with radiotherapy and chemo-
therapy. Also, borderline ovarian cancer represents a diffi-
cult task for diagnosis, and it can proceed into an
aggressive, resistant, and lethal disease. Ovarian cancer
often results in the remission of disease and lethality, and
its manifestation is still poorly understood. The aggressive
character of ovarian cancer is attributed to cancer
stem cells [1–5]. Ovarian cancer stem cells are widely
researched using established markers such as aldehyde
dehydrogenase (ALDH1) [6–10] or leucine-rich, repeat-
containing G protein-coupled receptor 5 (LGR5) [11–15],
mostly in ovarian cancer cell lines (e.g., OVCAR3, SKOV3,
IGROV1) in vitro. In spite of that, there is still no gen-
erally accepted population of ovarian cancer tumor-
initiating stem cells in terms of their phenotype and
molecular status. The study of ovarian cancer lines does
not necessarily reflect the situation in vivo. Moreover,
there might be different populations of stem cells co-
acting in the manifestation and invasion of ovarian
cancer at different stages of progression [16–18].
Our group has discovered small stem cells with diame-
ters of 2–4 μm in adult human ovaries [19, 20] which
can be sorted from the ovarian tissue [21] and pushed
into developing primitive oocyte-like cells in vitro in the
presence of follicular fluid containing several substances
important for growth and maturation of oocytes [22].
These small stem cells are mostly located in the ovarian
surface epithelium [22, 23] and express several genes re-
lated to pluripotency (e.g., NANOG, SALL4, LIN28B,
LEFTY, ZIC3 and LEFTY1) and germinal lineage (e.g.,
VASA/DDX4), especially primordial germ cells (PGCs)
(e.g., PRDM14), as evidenced by transcriptomics [24].
They have also been found in adult human ovaries by
some other research groups [25] and in the ovaries of
other mammalian species such as rabbit, sheep, monkey
[25], mouse [26], and pig [27]. Due to the character of
these small stem cells, the possibility is not excluded that
they could also be involved in the manifestation of
ovarian cancer. Ovarian small stem cells are quite com-
parable to very small embryonic-like stem cells (VSELs)
from human bone marrow [28, 29] and peripheral [30]
and umbilical cord blood [31], discovered by the Ratajczak
research group. The origin of these VSELs has been sug-
gested to lie in the embryonal epiblast and then persist in
adult human tissues and organs from the embryonic
period of life in a quiescent state [32–35]. VSELs seem to
be epigenetically “locked” to prevent teratoma formation
in human adult tissues and organs [35] but are proposed
to form tumors upon inappropriate conditions in the body
[36]. Some other groups reported on the oogonial stem
cells in adult human ovaries which may represent the
descendants of small ovarian stem cells [37]. Furthermore,
in several studies it has been reported that mesenchymal
stem cells (MSCs) can also express some markers of pluri-
potency, are important for spreading and the invasion of
tumors, and support cancer stem cells [38–49]. Putative
ovarian MSCs have already been successfully cultured and
differentiated in vitro in humans [50]. Moreover, the
epithelial-mesenchymal transition has been proposed to
play an important role in the manifestation of ovarian can-
cer and its resistance to therapy [51–67].
The aim of this study was to identify potential ovarian
stem cells in situ in ovarian sections of women with
borderline ovarian cancer or high-grade serous ovarian
carcinoma using immunohistochemistry for pluripotency-
related NANOG, which is known to be involved in prolif-
eration and self-renewal of pluripotent stem cells [68].
The marker NANOG has been analyzed on account of
our previous finding that this marker is strongly expressed
in small stem cells from adult human ovaries, [24] and its
expression in cancerous ovaries has already been related
to ovarian cancer in terms of poorer outcome in ovarian
epithelial malignancies [69]. Furthermore, the expression
of SOX2 and SSEA-4 markers, related to pluripotency,
was analyzed to compare it with NANOG expression in
ovarian sections. Our special emphasis has been devoted
to small ovarian stem cells, which are usually not moni-
tored by histopathologists because of their small size and
unknown clinical significance.
Methods
This study has been approved by the Slovenian Medical
Ethical Committee (Ministry of Health of the Republic
of Slovenia, No. 135/09/09 and 154/07/10) in the frame
of ovarian stem cell research and is in compliance with
the Helsinki Declaration. The ovarian tissue sections of
47 women: 27 women with borderline ovarian cancer and
20 women with high-grade serous ovarian carcinoma were
collected at our Histopathology Unit to perform histo-
pathological diagnosis and were then included into this
study. Ovarian tissue sections were stained by hematoxylin
and eosin (HE) staining, common in daily medical prac-
tice, which resulted in blue-stained nuclei of cells.
Using immunohistochemistry, the ovarian tissue sec-
tions of 19 women with borderline ovarian cancer and
20 women with serous ovarian cancer were analyzed on
pluripotency-related marker NANOG, expressed in the
nucleus, to identify the potential stem cells expressing
this marker and their localization in the ovary. We
particularly focused on small putative stem cells with
diameters of up to 5 μm expressing a degree of pluripo-
tency which had previously been discovered in ovarian
cell cultures in vitro. In three women with high-grade
serous ovarian carcinoma the ovarian sections were
Virant-Klun et al. Journal of Ovarian Research  (2016) 9:12 Page 2 of 15
further stained for pluripotency-related markers SSEA-4
and SOX2.
Immunohistochemistry (IHC) for NANOG
IHC analysis was performed on a tissue microarray
(TMA) of tissue samples from women with ovarian bor-
derline cancer and high-grade serous ovarian carcinoma.
After evaluation of all HE stained sections of ovarian tis-
sue/tumor, the representative areas of the ovarian/tumor
tissue were marked and biopsy was performed using a
2 mm core needle. The corresponding ovarian/tumor tis-
sue was then transplanted to multitumor paraffin blocks.
Consecutively, 3–5 μm sections were cut from each multi-
tumor block. The paraffin sections were then placed on
silane-coated slides (Menzel-Glaser Superfrost) and dried
in a dryer for one hour at 60 °C. The immunohistochemi-
cal staining was performed in an automatic slide stainer
(Ventana BenchMark GX). After deparaffinization, anti-
gen retrieval (HIER) was performed at pH 7–8 for 48 min
with CC1 Ventana reagent. This was followed by hand ap-
plication of the primary antibody. To do this, the slides
were incubated with rabbit anti-human NANOG mono-
clonal antibody (ab109250, Abcam Cambridge, MA, USA)
at dilution 1:25 for 30 min at 37 °C. For antigen detec-
tion, a Ventana OptiView Kit was used. The testicular
embryonal carcinoma tissue, treated in the same way,
was used as a positive control, and elimination of the
primary antibody served as a negative control. In each
woman up to 2 ovarian sections were stained. The stained
slides were monitored under a light microscope (at magni-
fications up to 1000x), common in histopathology, but
also under an inverted microscope (at magnifications up
to 200x) to better elucidate the potential stem cells. After
HE staining, the cell nuclei were stained blue and the
NANOG-positivity was expressed by the color brown. We
focused on nuclear NANOG staining which matched with
blue HE staining.
Immunohistochemistry for SSEA-4 and SOX2
Paraffin embedded ovarian tissue was cut into 4 μm
thick sections, mounted on silanized slides and dried at
37 °C overnight. Next morning the sections were depar-
affinised with xylene (2 washes for 10 min) and rehy-
drated through a graded ethanol series; the sections
were rinsed twice for 2 min in absolute ethanol and then
four times for 1 min subsequently in 96 %, 80 %, 50 %
and 30 % ethanol. Then the sections were rinsed for
2 min in tap water. For antigen retrieval the sections
were boiled in Target Retrieval Solution (Dako) for
10 min at low power in a microwave oven. After cooling
down, the sections were rinsed with PBS. When intracellu-
lar antigen was observed, the sections were permeabilized
with 0.3 % Triton X-100 for 10 min and rinsed with PBS.
The following procedures were the same for detecting
intracellular or surface antigens. Unspecific binding sites
were blocked with 10 % fetal bovine serum (the sections
were incubated for 30 min) and then the antibodies were
applied. The tissue sections were incubated for 2 h in
mouse anti-SSEA-4 FITC-conjugated (diluted 1:200) or
mouse anti-SOX2 PE-conjugated (diluted 1:100) anti-
bodies (both BD Biosciences). After rinsing the tissue
sections several times with PBS, the slides were mounted
with Vectashield mounting medium with DAPI (Vector
Laboratories) and observed under fluorescent microscope.
After DAPI staining the cell nuclei were stained blue. The
SSEA-4-positive cells expressed surface green fluorescence
and SOX2-positive cells expressed nuclear red fluores-
cence. We focused on SSEA-4 and SOX2-positivity
matched with blue DAPI staining of nuclei.
Results
Ovarian surface epithelium
As expected, small round cells were observed in ovarian
surface epithelium after HE staining and some of them
also expressed NANOG-positivity (brown staining) in
both ovarian tissue sections of women with borderline
ovarian cancer and high-grade serous ovarian carcinoma
(Fig. 1). The NANOG-positive cells were of sizes up to
5 μm and were located among epithelial cells without
any special order (Fig. 1a-d, g, h) or just below them
(Fig. 1e and f). The entire cells were positively stained
for NANOG due to large nuclei filling almost the whole
cell volumes; in some cells it was clear that they had
almost no cytoplasm around the positively stained nuclei
(e.g., Fig. 1b and c). The NANOG-positive staining
matched with blue HE staining of nuclei.
Small round cells in non-defined “chambers”
In addition to NANOG-positive cells among epithelial
cells of ovarian surface epithelium, there were also small
single cells of the same sizes or groups of cells, which
were NANOG-positive and were located in special, non-
defined “chambers” of unknown origin. These “chambers”
seem to be special structures with empty space, containing
single or groups of small cells with diameters of up to
5 μm, and were arranged tightly among other types of
cells in both borderline ovarian cancer and high-grade ser-
ous ovarian carcinoma (Figs. 2, 3, 4 and 5 and Additional
file 1: Figure S1). In some “chambers” these small cells
seem to divide and form cluster-like structures. They
appeared in several places of completely non-damaged
ovarian tissue and were not a matter of tissue degradation.
The “chambers” with small cells were clearly seen after
HE staining, as shown in Fig. 2 and were present in
ovarian sections of all women included in this study
who suffered from both borderline ovarian cancer and
serous ovarian carcinoma. In spite of this, our impres-
sion was that these “chambers” were more abundant in
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the tissue of borderline ovarian cancer than in serous
ovarian carcinoma, while present in both types of
tissue. It was impossible to count these “chambers”
because they were quite abundant. Cells in these
“chambers” were small, round and with nuclei that
filled almost the whole cell volumes. The “chambers”
were mostly located in the ovarian surface epithelium
layer among epithelial cells, just below it or inside the
“islands” of epithelial cells inside the ovarian tissue
(Figs. 2 and 3, Additional file 1: Figure S1). In the
vicinity of these “chambers” the ovarian surface epithe-
lium was morphologically changed: epithelial cells had
proliferated, appearing in more layers, and the typical
shape of epithelial cells was drastically changed (e.g.,
extended cells), as shown in Fig. 2 and Additional file 1:
Figure S1. In two patients with high-grade serous
ovarian carcinoma these “chambers” were spread over
all ovarian tissue sections, as can be seen in Fig. 4.
Moreover, two patients with serous ovarian carcinoma
showed big, specific “chambers” appearing in the tissue,
Fig. 1 NANOG-positive cells (arrows) in the ovarian surface epithelium. They appeared among epithelial cells (a-d, g, h) without any special order,
or just below them (e and f) in women with borderline ovarian cancer and high-grade serous ovarian carcinoma. (Light microscope: a-c, f,
magnification 1000x; inverted microscope: d, e, g, h, magnifications 100x or 200x). Legend: brown-NANOG-positivity, blue-nuclei after HE staining.
Red Bar: 100 μm for a-c, f, 50 μm for d and 10 μm for e, g, h
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which contained several small, separated cells with
diameters of up to 5 μm and nuclei filling almost the
whole cell volumes (see Fig. 5). These “chambers” were
not blood vessels because there were no erythrocytes or
other typical blood cells in them, and they were not
surrounded by muscular but epithelial/cancer cells.
Interestingly, comparable “chambers” including oocyte
progenitor cells were found in fetal ovaries yet were not
present in the ovaries of healthy women without cancer
(Additional file 2: Figure S2).
A proportion of small round cells in such “chambers”
was positively stained for NANOG (Figs. 3, 4 and 5). In
NANOG-positive cells the whole cells were stained
brown, thus indicating that the nuclei filled almost the
whole cell volumes. Beside this, in the regions with
“chambers”, including the NANOG-positive cells, the
Fig. 2 Special “chambers” containing small, round cells (arrows) or groups/clusters (asterisks) of these cells. The diameter of these small, round cells
was up to 5 μm with nuclei filling almost the whole cell volumes. They were located among epithelial cells or just below them in ovarian sections of
women with borderline ovarian cancer after hematoxylin-eosin (HE) staining (a-h). In the vicinity of these “chambers” the ovarian surface epithelium
was drastically changed with several layers of proliferated epithelial cells, epithelial cells of atypical shapes (e.g., extended) and formation of papillae.
(Light microscope, magnification 1000x). Red Bar: 100 μm
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surrounding epithelial cells were also more or less posi-
tively stained for NANOG (Figs. 3d-f and 4f-h), while
more distant cells were not.
Tumor-like structures in “chambers”
In a relatively small proportion of the “chambers” some
structures with diameters of up to 50 μm and resembling
tumors were observed after HE staining (Fig. 6a and b).
They were “closed” in growing “chambers”, although the
tissue in their vicinity was mostly damaged and blood ves-
sels were found to be close to them. Similar structures
were found in ovaries from women with both borderline
ovarian cancer and serous ovarian cancer. These tumor-
like structures were clearly seen after HE staining of
Fig. 3 Small NANOG-positive cells (arrows) with diameters of up to 5 μm in “chambers”. These “chambers” containing small, round, NANOG-positive cells
were located among epithelial cells in ovarian tissue sections of women with high-grade serous ovarian carcinoma (a-f). The surrounding epithelial cells
also became NANOG-positive in some places (d-f), as possibly influenced by small cells in those “chambers”. Controls were provided: negative
control (g) and positive control-testicular embryonal carcinoma with strongly stained cells in seminiferous tubules (h) (Light microscope: a,
magnification 1000x; inverted microscope: b-h, magnifications 40x, 100x and 200x). Legend: brown-NANOG-positivity, blue-nuclei after HE
staining. Red Bar: 10 μm for b-d, 50 μm for f, h and 100 μm for a, e, g
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ovarian tissue (Fig. 6a and b), and very similar structures
were positively stained for NANOG, as can be seen in
Fig. 6c-g. A small proportion of tumor-like structures in
the same “chambers” were mineralized (Fig. 6b) but in
borderline ovarian cancer only; it was no longer possible
to see the nuclei in these structures. On the other hand, it
was clearly visible that some of tumor-like structures were
composed of small cells (Fig. 6g), which were NANOG-
positive, especially in the ovarian tissue of women with
serous ovarian carcinoma.
Primitive oocyte-like cells in “chambers”
Interestingly, primitive oocyte-like cells were found in
some similar but rare “chambers” (Fig. 7). These cells
were round, with diameters of up to 30 μm, and some of
them expressed tiny zona pellucida-like structures (Fig. 7a).
Fig. 4 Highly abundant “chambers” containing small, round cells (arrows) or clusters of cells (asterisks) in ovarian tissue. They were present in
borderline ovarian cancer (a-c) and high-grade serous ovarian carcinoma (d-h) tissue. In a proportion of “chambers” the small, round cells were
NANOG-positive and were stained brown. (Light microscope: a-c, magnifications 200x or 1000X; inverted microscope: d-h, magnifications 40x and
100x). Legend: brown-NANOG-positivity, blue-nuclei after HE staining. Red Bar: 100 μm for a-d and 50 μm for e-h
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The primitive oocyte-like cells were present in these non-
defined “chambers” and not in follicles (Additional file 2:
Figure S2). These primitive oocyte-like cells were observed
in the ovarian tissue of women with borderline ovarian
cancer after HE staining (Fig. 7a) and also in women with
serous ovarian carcinoma (Fig. 7b-e). The primitive
oocyte-like cells, which can be seen in Fig. 7b-e were
developed in the ovarian tissue of one patient with
serous ovarian carcinoma and were positively stained
for NANOG. The structure of their cytoplasm was quite
comparable to human oocytes. Actually, the primitive
oocyte-like cells appeared inside the ovarian tumor of
high-grade serous carcinoma. Moreover, these primitive
oocyte-like cells seem to develop from small round cells
with diameters of up to 5 μm, which were strongly positive
for NANOG, and were attached to them, as can be seen
from Fig. 7b-e. These small, NANOG-positive cells were
growing and reached different sizes up to 30 μm.
Fig. 5 Ovarian tissue sections with “chambers” of different shapes containing groups of small, round cells (arrows). These small cells had diameters of
up to 5 μm. Their nuclei filled almost the whole cell volumes in two patients with high-grade serous ovarian carcinoma after HE staining (a-f). A
proportion of these cells were NANOG-positive (g and h). “Chambers” were surrounded by epithelial/cancer cells. Figures a, b, c, e and f show the
same structures at different magnifications to get better insight. (Light microscope: a-g, magnifications 100x, 200x and 1000x; inverted microscope:
h, magnification 200x). Legend: brown-NANOG-positivity, blue-nuclei after HE staining. Red Bars: 10 μm for h and 100 μm for a-g
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SSEA-4 and SOX2-positive cells in ovarian sections
Similar populations of SSEA-4 and SOX2-positive cells
were found in ovarian surface epithelium and typical
“chambers”, as can be seen in Fig. 8. The small SSEA-4
and SOX2-positive cells with diameters of up to 5 μm
were proliferated in the layer of ovarian surface epithe-
lium. Single small SSEA-4 and SOX2-positive cells were
present in “chambers” and atrophic (autofluorescent)
ovarian tissue was found in their vicinity. This observa-
tion further confirmed the above findings on NANOG
expression.
Discussion
The aim of our study is not to provide a new diagnostic
tool for ovarian cancer but to identify in situ the small pu-
tative stem cells, which previously had been discovered in
Fig. 6 Tumor-like structures (arrows) developed in “chambers” present in ovarian tissue (a-g). They were present in ovaries of women with borderline
ovarian cancer and high-grade serous ovarian carcinoma. The tumor-like structures were strongly NANOG-positive (c-g). A small proportion of tumor-like
structures in borderline ovarian cancer was mineralized and with no visible nuclei (b). Some tumor-like structures were composed of small
cells with clearly visible nuclei (g). (Light microscope: a-d, g, magnification 100x and 1000x; inverted microscope: e-f, magnification 200x).
Legend: brown-NANOG-positivity, blue-nuclei after HE staining. Red Bars: 100 μm for a-d, g and 10 μm for e, f
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human ovarian cell cultures in vitro. They were found in
the ovarian surface epithelium. Furthermore, our observa-
tion showed that in ovarian tissue sections from patients
with borderline ovarian cancer and high-grade serous
ovarian carcinoma there are non-defined “chambers” of
unknown origin. These “chambers” are interesting because
they contain small round cells with diameters of up to
5 μm or groups/clusters of these cells, which were posi-
tively stained for pluripotency-related NANOG. Moreover,
in some of these “chambers” tumor-like structures and
primitive oocyte-like cells were observed. Our data indi-
cate that these “chambers” may include putative stem
cells, which may be involved in tumor formation and
oogenesis.
The results of this study in situ may confirm the previous
finding that in adult human ovaries [19–21, 24, 25] and
ovaries of some other mammalian species [25–27] such as
rabbit, sheep, marmoset monkey, pig and mouse there is a
population of small stem cells with diameters of about 2 to
4 μm, which express a specific pattern of pluripotency, in-
cluding NANOG [24], and resemble VSELs discovered in
adult human bone marrow [28, 29], peripheral blood [30]
and cord blood [31] by the Ratajczak research group.
These small stem cells are mostly located in the ovarian
surface epithelium of adult ovaries [19–21, 23, 25]. Also in
this study small, NANOG-positive cells were indeed found
in the layer of ovarian surface epithelium among epithelial
cells or just below them. Other than in “healthy” ovaries,
similar small, NANOG-positive cells were present in
special “chambers” of unknown origin in the ovaries of
women with borderline ovarian cancer or high-grade
serous ovarian carcinoma. The small round cells possessed
Fig. 7 Primitive oocyte-like cells in “chambers” present in ovarian tissue. They were present in borderline ovarian cancer (a) and high-grade serous
ovarian carcinoma tissue (b-e). The primitive oocyte-like cells were slightly NANOG-positive (b-e) and small, round, NANOG-positive cells (arrows)
were attached to them. The oocyte-like cells appeared from these small cells inside the ovarian tumor. The structure of cytoplasm in these cells
was quite comparable to human oocytes. Figures b-e show the same structures at different magnifications to get better insight. (Light microscope:
a, magnification 1000x; inverted microscope: b-e, magnifications 200x). Legend: O-oocyte-like cell. Legend: brown-NANOG-positivity, blue-nuclei after HE
staining. Red Bars: 100 μm for (a), 50 μm for (b) and 10 μm for (c-e)
Virant-Klun et al. Journal of Ovarian Research  (2016) 9:12 Page 10 of 15
two important features of stem cells: nuclei filling almost
the whole cell volumes and strong nuclear staining for
pluripotency-related marker NANOG. Similar populations
of SOX2 and SSEA-4-positive cells were found in ovarian
sections of women with high-grade serous ovarian
carcinoma and their expression nicely matched with
NANOG expression.
We were searching the literature for a description of
such “chambers” but were able to find only data on
psammoma bodies [70–73], which are described as
round collections of calcium with a laminar appearance
and which are usually associated with the papillary his-
tomorphology of different cancers, including serous
ovarian carcinoma, and are thought to arise from the
infarction and calcification of papillae tips and calcifica-
tion of intralymphatic tumor thrombi. The psammoma
bodies can also appear in chamber-like arrangements,
but our data clearly show that cancerous ovarian tissue
Fig. 8 Small putative stem cells (arrows) expressing SSEA-4 and SOX2-positivity after immunohistochemistry and blue nuclei after DAPI staining of
ovarian sections. Small SSEA-4 and SOX2-positive cells were proliferated in ovarian surface epithelium or were found in typical “chambers” with
atrophic and autofluorescent (af) tissue nearby. Legend: green-SSEA-4-positivity, red-SOX2-positivity, ose-ovarian surface epithelium, af-autofluorescence,
er-erythrocytes (without nuclei). Red bars: 10 μm
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“chambers” definitely do not contain calcium, instead,
small, round cells or clusters of these cells are present.
These small NANOG-positive cells might be proposed
as lymphocytes (i.e., immunological infiltrates), but
lymphocytes, in general, are of bigger sizes; small lym-
phocytes have diameters of 7 to 10 μm and large lym-
phocytes from 14 to 20 μm according to the Atlas of
Microscopic Anatomy [74]. Moreover, the lymphocytes
definitely do not express the pluripotency-related
marker NANOG. The specific “chambers” that contain
small NANOG-positive cells may further be proposed
to be free spaces filled with cell debris in atrophic parts
of ovarian tissue; however, the special “chambers”
observed in this study also appeared in completely un-
damaged ovarian tissue and contain completely round
cell-like structures with blue stained nuclei, which posi-
tively stained for NANOG. Upon such description, one
may propose these “chambers” to be vacuolated cancer
cells and autophagy, but this phenomenon looks com-
pletely different when observed in situ [75].
Moreover, tumor-like structures and even primitive
oocyte-like cells, positive for NANOG, were found in
similar “chambers”, indicating that they might develop
from small putative stem cells expressing NANOG,
within these “chambers”. Our preliminary experimental
data, published as a case report in this journal, showed
that small cells in “chambers” in the ovaries of an aged
woman with serous papillary adenocarcinoma have also
expressed other markers of pluripotency and germinal
lineage, which were proposed to be primitive germ
cells either persisting from the fetal period of life or
developed from putative stem cells [76]. Other tissue
in which we were indeed able to observe similar
“chambers” containing small cells was the fetal ovaries.
In fetal ovaries, the tissue was expanded by comparable
“chambers”, which contained oocyte progenitor cells.
Based on this observation, some similarity between the
morphology of cancerous ovaries and fetal ovaries can be
suggested. An important question arose as to whether the
early follicles, i.e., “chambers”, containing pluripotent
germ cell progenitors, persisting from the fetal period of
life, may be related to the manifestation of ovarian cancer.
In our previous research, small stem cells have been ob-
served in ovarian surface epithelium of “healthy” ovaries,
but were not present inside such “chambers”.
At several places the epithelial cells in the vicinity of
these “chambers” containing small putative stem cells were
drastically changed; they had proliferated and appeared in
more layers, and they expressed an atypical changed shape
(e.g., formation of papillae). We suggest that small putative
stem cells in cancerous ovaries, especially those in “cham-
bers”, affect the surrounding epithelial cells and possibly
trigger them to change by an unknown mechanism such as
cell secretion, epithelial-mesenchymal transition [51–67]
or something else. The experimental results from the
literature indeed showed that cancer cells in epithelial
ovarian cancers express a strong cytoplasmic expres-
sion of pluripotency-related NANOG [69].
The observation of NANOG-positive primitive oocyte-
like cells in “chambers” of cancerous ovaries, which very
possibly developed from small putative stem cells,
strongly expressing NANOG and are attached to them,
confirms the previous observation on small putative
stem cells in adult human ovaries that may develop into
primitive oocyte-like cells in vitro, for example in the
presence of follicular fluid rich on substances important
for oocyte growth and maturation in humans [19, 20, 22,
25, 37] and in some other mammalian species such as
mouse [26], pig [27], and marmoset monkey [77]. The
development of stem cells into oocyte-like cells in vitro
represents an important confirmation of the pluripotent
character of stem cells, as experienced in embryonic
stem cells (ESCs) [78] and human induced pluripotent
stem cells (hiPSCs) [79].
Conclusions
The small putative stem cells with diameters of up to
5 μm, expressing pluripotency-related markers NANOG,
SOX2 and SSEA-4 which were identified in the ovarian
sections of the women suffering from borderline ovarian
cancer or high-grade serous ovarian carcinoma included
into this study, were present in the ovarian surface epithe-
lium and in special, non-defined “chambers”. Our observa-
tion indicates that they may be involved in tumorigenesis
and oogenesis. This observation is consistent with the idea
of very small embryonic-like stem cells (VSELs), which
have already been discovered in other adult human tissues
and organs, such as bone marrow, and are suggested to ori-
ginate from embryonic epiblast, relate to primordial germ
cells (PGCs) that persist from the embryonic period of life
and are involved in the regeneration of damaged tissues
and organs. On the other hand, these small stem cells
may form tumors in inappropriate conditions in the
body [32–36]. Our results indicate that further research
of small putative stem cells and “chambers” in situ is
needed through the application of other markers, related
to stem cells, pluripotency, germinal lineage, and cancer
in order to maybe better understand the manifestation of
ovarian cancer in the future.
Additional files
Additional file 1: Figure S1. “Chambers” (arrows) containing small cells
in ovarian surface epithelium of women with borderline ovarian cancer.
Epithelial cells in the vicinity of “chambers” were drastically changed in
terms of shape and proliferation (a-f), as observed after HE staining.
(Inverted microscope: a-e, magnification 200x; light microscope: f, magni-
fication 1000x). Legend: blue-nuclei, e-epithelial cells. Red Bars: 10 μm for
a-e and 100 μm for f. (JPG 1446 kb)
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Additional file 2: Figure S2. Sections of ovaries in borderline ovarian
cancer, fetal ovary, and women of reproductive age. In borderline ovarian
cancer (a) and fetal ovary (b) comparable “chambers” (arrows) containing
small round cells have been observed. In “chambers” of fetal ovaries the
oocyte progenitor cells are present. No comparable “chambers” have
been observed in ovaries of women of reproductive age: fertile women
(c) with follicles in ovarian cortex, and women with premature ovarian
failure (d) without follicles in the ovarian cortex. In cancerous ovaries
early follicles containing primitive oocytes were still found in “normal”
ovarian cortex tissue (e). (Light microscope: a-e, magnifications 100x, 200x
and 1000X). Legend: F-follicle. Red Bars: 100 μm. (JPG 1981 kb)
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